137 results about "Skeletal muscle cell" patented technology

This invention also provides a purified or isolated population of ADSCs that can differentiate into a cell of the leiomyogenic lineage, e.g., smooth muscle or skeletal muscle. In yet another aspect, the population additionally can be differentiated into a lineage selected from the group consisting of osteogenic, adipogenic, chondrogenic, myogenic and neuronal. This invention further provides a composition comprising a substantially homogeneous expanded population of smooth muscle cells. This invention provides a composition comprising a substantially homogeneous expanded population of skeletal muscle cells. Also provided herein is an isolated composition comprising a purified adipose-derived stem cell (ADSC) or progeny of said ADSC and an effective amount of laminin or heparin, effective to induce leiomyogenic differentiation. Diagnositic and therapeutic uses for these compositions are provided herein.

A monoclonal antibody, 3E10, and active fragments thereof that selectively are transported in vivo to the nucleus of mammalian cells without cytotoxic effect are provided. The antibody and other molecules that bind to a variant of myosin IIb heavy chain found in the nucleus of skeletal muscle cells are useful as a non-viral delivery vector to target skeletal muscle in vivo. By contrast, in vitro the monoclonal antibody penetrates and is transported to the nucleus of multiple cell lines derived from different tissue types and can be used in screening tests to identify molecules that modulate growth of cells, such as cancer cells. Non-cytotoxic vectors for delivering a drug, polynucleotide or polypeptide selectively to skeletal muscle cells are also provided.

There is provided a method of inducing differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells by introduction of a Notch gene. Specifically, the invention provides a method of inducing differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells in vitro, which method comprises introducing a Notch gene and / or a Notch signaling related gene into the cells, wherein the finally obtained differentiated cells are the result of cell division of the bone marrow stromal cells into which the Notch gene and / or Notch signaling related gene have been introduced. The invention also provides a method of inducing further differentiation of the differentiation-induced neural cells to dopaminergic neurons or acetylcholinergic neurons. The invention yet further provides a treatment method for neurodegenerative and skeletal muscle degenerative diseases which employs neural precursor cells, neural cells or skeletal muscle cells produced by the method of the invention.

There is provided a method of inducing differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells by introduction of a Notch gene. Specifically, the invention provides a method of inducing differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells in vitro, which method comprises introducing a Notch gene and / or a Notch signaling related gene into the cells, wherein the finally obtained differentiated cells are the result of cell division of the bone marrow stromal cells into which the Notch gene and / or Notch signaling related gene have been introduced. The invention also provides a method of inducing further differentiation of the differentiation-induced neural cells to dopaminergic neurons or acetylcholinergic neurons. The invention yet further provides a treatment method for neurodegenerative and skeletal muscle degenerative diseases which employs neural precursor cells, neural cells or skeletal muscle cells produced by the method of the invention.

The present invention relates to multipotent stem cells derived from the interstitial tissues of skeletal muscle. The multipotent stem cell of the present invention is capable of differentiating into skeletal muscle cells, smooth muscle cells, cardiomyocytes, blood cells, vascular endothelial cells, adipocytes, osteoblasts, nervous cells, hepatocytes and pancreatic cells, and is useful for regeneration of tissues and cells and treatment for cardiac failure, hepatic insufficiency, renal insufficiency, leukemia, nerve degeneration disease, arthritis, diabetes, arteriosclerosis, and the like.

This invention also provides a purified or isolated population of ADSCs that can differentiate into a cell of the leiomyogenic lineage, e.g., smooth muscle or skeletal muscle. In yet another aspect, the population additionally can be differentiated into a lineage selected from the group consisting of osteogenic, adipogenic, chondrogenic, myogenic and neuronal. This invention further provides a composition comprising a substantially homogeneous expanded population of smooth muscle cells. This invention provides a composition comprising a substantially homogeneous expanded population of skeletal muscle cells. Also provided herein is an isolated composition comprising a purified adipose-derived stem cell (ADSC) or progeny of said ADSC and an effective amount of laminin or heparin, effective to induce leiomyogenic differentiation. Diagnositic and therapeutic uses for these compositions are provided herein.

The present invention describes microRNAs that regulate the differentiation, proliferation and death of cardiac and skeletal muscles cells. These molecules represent unique targets in the developmental pathways of muscle cells. They also can be used as active agents to induce differentiation in progenitor cells, and their down-regulation permits the maintenance and expansion of progenitor cell populations.

Disclosed is a method for culturing myocardium-resident cardiac progenitor cells, comprising: embedding myocardial fragments into hydrogel; culturing the myocardial fragment into hydrogel; degrading only the hydrogel to recover cardiac progenitor cells grown out of the myocardial fragment to the hydrogel; and amplifying the cardiac progenitor cells in vitro. Also, the cardiac progenitor cells, a method for differentiating the same, and the use thereof as cell therapeutic agent for heart diseases are provided. In addition to possessing the potential to differentiate into cardiomyocytes, osteoblasts, adipocytes, chondrocytes, vascular endothelial cells, smooth muscle cells, neural cells, and skeletal muscle cells, the myocardium-resident cardiac progenitor cells can spontaneously differentiate into cardiomyocytes even in the absence of a special differentiation inducing agent. Thus, the cardiac progenitor cells can be used to produce bio-active medicines such as cell therapeutics and tissue engineering therapeutics with high industrial applicability.

The invention discloses a method for separately culturing a human adipose mesenchymal stem cell and a dedicated culture medium thereof. The culture medium used for separately culturing the human adipose mesenchymal stem cell comprises an animal cell basic culture medium, fetal calf serum, an epidermal growth factor and a platelet-derived growth factor. The final concentration of the fetal calf serum is 1-200 mL / L, the final concentration of the epidermal growth factor is 1-100 ng / ml, and the final concentration of the platelet-derived growth factor is 1-100 ng / ml. The adipose mesenchymal stem cell of the invention has CD31-, CD34-, CD45- and HLA-DR-, as well as the phenotype of CD29+, CD44+, CD105+ and Flk-1+. The specificity cell surface marker and the relevant antihelion molecule of a skeletal muscle cell and a vascular endothelia cell can be expressed after inducement is performed in vitro. Muscle fiber, vascular endothelin and functional muscle satellite cells can be differentiated in a muscle injury model mouse body caused by medicine and the expression of dystrophin protein on the ducheme muscular dystrophy (DMD) model mouse (mdx) myolemma can be partially recovered, so as to release the pathological symptom of the model mouse.

The invention provides methods for establishing electrical coupling between cardionyocytes and recombinant cells which have been genetically engineered to express a gap junction protein, eg., Connexin protein such as Connexin 43 (CX43) protein, n invention is based on the discovery that genetic modification of skeletal muscle cells to express a recombinant connexin, enables the genetically modified cells to establish electrocommunication with cardiac cells via gap junctions. The recombinant connexin-expressing cells can be used for repair of cardiac issue and for treatment of cardiac disease by transplantation into cardiac tissue.

Methods and compositions are provided for lineage predetermination of cellular transplants including through liposome mediated transfection with aqueous protein extracts from populations of differentiated mammalian cells, or cellular fractions thereof, wherein the differentiated mammalian cells are enriched in one or more of adipocytes, chondrocytes, endothelial cells, hepatocytes, cardiomyocytes, smooth muscle cells, skeletal muscle cells, cardiac pacemaker cells, Schwann cells, pancreatic islet cells, hematopoietic cells, myeloblasts, neurons, and osteoblasts.

Expression of the E4 orf 1 gene of Ad-36 alone has been discovered to be responsible for the increased insulin sensitivity observed in Ad-36 infected animals, including increased adipogenesis. Ad-36 E4 orf 1 protein can be used to increase insulin sensitivity and ameliorate diabetes. Additionally, drugs that mimic the action of Ad-36 E4 orf 1 protein could be found. Ad-36 E4 orf 1 could also be used to increase fat cells in lipodystrophy. We have also discovered that Ad-36 infection in human skeletal muscle cells increased differentiation and insulin independent glucose uptake. It is expected that infection with Ad-36 E4 orf 1 gene will also cause these effects.

Compositions and methods for modulating activity of store-operated calcium entry in cells or tissues are provided. The compositions comprise the P311 protein, fused to a cell-penetrating peptide and formulated for delivery to tissues and cells. This protein has been shown to increase the levels of store-operated calcium entry (SOCE) in gingival cells, skeletal muscle cells, and prostate epithelial cells. Also provided are methods for preventing and treating diseases that involve administration of the P311 fusion protein, as well as methods for increasing levels of SOCE in cells.

It is an object of the present invention to provide a cell-containing composition capable of suppressing the outflow of the cells after transplantation and improving the survival rate of the cells. The present invention provides a composition which comprises any of bone marrow stromal cell-derived neural precursor cells, bone marrow stromal cell-derived Schwann cells, or bone marrow stromal cell-derived skeletal muscle cells; and a biocompatible polymer.

The invention provides methods for establishing electrical coupling between cardiomyocytes and recombinant cells which have been genetically engineered to express a connexin protein such as connexin 43 (Cx43) protein. The invention is based on the discovery that genetic modification of skeletal muscle cells to express a recombinant connexin, enables the genetically modified cells to establish electrocommunication with cardiac cells via gap junctions. The recombinant connexin-expressing cells can be used for repair of cardiac tissue and for treatment of cardiac disease by transplantation into cardiac tissue.

The invention discloses a method for culture of urine-derived pluripotent stem cells by virtue of in vitro small molecule induction. The method comprises the following steps: obtaining urine-derived cells from a human urine sample; carrying out in vitro small molecule induction and culturing on the obtained primary cells to obtain P1 generation hUSCs clones growing with adherence; picking up the hUSCs clones in good growing state to inoculate; and continuously carrying out continuous cell culture to obtain hUSCs with the cells which are elongated and good in state. The hUSCs prepared by the method disclosed by the invention, by virtue of induction, can be directionally differentiated to osteoblasts, adipose cells, skeletal muscle cells, nerve cells, fibroblasts or smooth muscle cells. The hUSCs are transplanted into a diabetic lower extremity ischemia model, and research results show that the hUSCs can remarkably enhance blood flow recovery and angiogenesis in an ischemia part. The hUSCs prepared by the method can be applied to treating and repairing diseased tissues and organs of diabetes and diabetic complications, cardiovascular, cerebrovascular and renovascular diseases, Alzheimer's disease, osteoporosis, arthritis and the like as well as early-warning tumors of the urinary system and screening cell drugs.

The invention provides methods for establishing electrical coupling between cardiomyocytes and recombinant cells which have been genetically engineered to express a gap junction protein, e.g., a connexin protein such as connexin 43 (Cx43) protein. The invention is based on the discovery that genetic modification of skeletal muscle cells to express a recombinant connexin, enables the genetically modified cells to establish electrocommunication with cardiac cells via gap junctions. The recombinant connexin expressing cells can be used for repair of cardiac tissue and for treatment of cardiac disease by transplantation into cardiac tissue.

The invention relates to a manufacturing method of an edible chitosan / sodium alginate / gelatin 3D scaffold for cell culture meat. The chitosan / sodium alginate / gelatin 3D scaffold manufactured by the method can be used for culture of skeletal muscle cells and can provide support for manufacturing of the cell culture meat. The invention belongs to the field of future food science and technology. According to the manufacturing method, chitosan with certain concentration, sodium alginate, gelatin and collagen are uniformly mixed according to a certain ratio, reacted at room temperature for more than 2 hours, and freeze-dried to obtain the chitosan / sodium alginate / gelatin 3D scaffold. The manufacturing method is simple and efficient, the 3D scaffold is formed through electrostatic interaction among the chitosan, the gelatin and the sodium alginate under the condition that a toxic cross-linking agent is not used, and the gelatin is used for partially replacing collagen to serve as a substance for promoting cell adhesion, so that the obtained chitosan / sodium alginate / gelatin 3D scaffold has good cell adhesion and compatibility, and can be used for skeletal muscle cell culture; the manufacturing method of the novel and non-toxic 3D scaffold is provided by the invention for the research of the cell culture meat.

The invention provides a method of co-culturing mammalian muscle cells and mammalian motoneurons. The method comprises preparing one or more carriers coated with a covalently bonded monolayer of trimethoxysilylpropyl diethylenetriamine (DETA); suspending isolated fetal mammalian skeletal muscle cells in serum-free medium according to medium composition 1; suspending isolated fetal mammalian spinal motoneurons in serum-free medium according to medium composition 1; plating the suspended muscle cells onto the one or more carriers at a predetermined density and allowing the muscle cells to attach; plating the suspended motoneurons at a predetermined density onto the one or more carriers and allowing the motoneurons to attach; covering the one or more carriers with a mixture of medium composition 1 and medium composition 2; and incubating the carriers covered in the media mixture.

The present invention provides a method of treating or preventing cardiac disorders in a subject in need thereof by inhibiting the expression or function of both miR-499 and miR-208 in the heart cells of the subject. In particular, specific protocols for administering inhibitors of the two miRNAs that achieve efficient, long-term suppression are disclosed. In addition, the invention provides a method for treating or preventing musculoskeletal disorders in a subject in need thereof by increasing the expression or activity of both miR-208 and miR-499 in skeletal muscle cells of the subject.

The present invention discloses a muscle atrophy preventing and relieving health-care food for the elderly, which is characterized in that the health-care food comprises the following raw materials in mass percentages: 60-70% of soybean oligopeptides, 16-22% of compound sweeteners, 10-15% of xylitol, 1-5% of siraitia grosvenorii extract, and 0.08-0.15% of citrus sinensis essence. The soybean oligopeptides in the health-care food can improve the activities of superoxide dismutase and glutathione peroxidase, inhibit lipid peroxidation, scavenge hydroxyl radicals, help to reduce tissue oxidation, and protect human body. Besides, the soybean oligopeptides can instantly repair damaged skeletal muscle cells during exercise, maintain the integrity of the structure and function of the skeletal muscle cells. At the same time, the health-care food can increase the secretion of testosterone and promote protein synthesis, which are conductive for the prevention and relieving of the elderly muscle atrophy.

Provided herein are scaffolds and methods useful to promote the formation of functional clusters on a tissue, for example, motor endplates (MEPs) or a component thereof on skeletal muscle cells or tissue, as well as the use of scaffolds so produced for repairing a tissue injury or defect.

The invention relates to culturing motor neuron cells together with skeletal muscle cells in a fluidic device under conditions whereby the interaction of these cells mimic the structure and function of the neuromuscular junction (NMJ) providing a NMJ-on-chip. Good viability, formation of myo-fibers and function of skeletal muscle cells on fluidic chips allow for measurements of muscle cell contractions. Embodiments of motor neurons co-cultures with contractile myo-fibers are contemplated for use with modeling diseases affecting NMJ's, e.g. Amyotrophic lateral sclerosis (ALS).

The present invention relates to an in vitro human neuromuscular junction model prepared from a co-culture of human pluripotent stem cell (PSC)-derived spinal motorneurons and human myoblast-derived skeletal muscle cells. The present invention also provides for methods of screening compounds for their ability to modulate neuromuscular junction activity by determining whether a candidate compound increases or decreases the activity of the in vitro human neuromuscular junction model.

The present invention provides a method of treating or preventing cardiac disorders in a subject in need thereof by inhibiting the expression or function of both miR-499 and miR-208 in the heart cells of the subject. In particular, specific protocols for administering inhibitors of the two miRNAs that achieve efficient, long-term suppression are disclosed. In addition, the invention provides a method for treating or preventing musculoskeletal disorders in a subject in need thereof by increasing the expression or activity of both miR-208 and miR-499 in skeletal muscle cells of the subject.

The invention discloses a layered co-culture method for intramuscular fat cells and skeletal muscle cells of a mammal. The layered co-culture method comprises the steps: after washing and cutting a longissimus tissue on the back of a butchered animal into pieces, digesting the longissimus tissue by using type-I collagenase, and sieving a digested mixed solution; collecting filtrate, centrifuging, respectively collecting mature fat cell sap on the upper layer and muscle cells on the lower layer, respectively adding a proper amount of serum-free medium to dilute and wash, and centrifuging; adding the centrifugate on the upper layer and the muscle cell sap on the lower layer into a culture flask with the capacity of 25cm<2>, and culturing in a culture box with the temperature of 37 DEG C and the CO2 content of 5%. The mature fat cells can float and adhere to a ceiling surface on the upper layer because of small buoyancy, while muscle cells sink to the bottom of the culture flask to grow. The cell culture model can be used for layering and co-culturing the intramuscular fat cells and the muscle cells of the same muscle tissue of an animal in the same culture solution, so that a novel in-vitro cell research model is provided for researching the influence of mature fat cell secreta to muscle cell differentiation or the interaction between the muscle cells and the fat cells.

The invention provides means and methods for transduction of a skeletal muscle cell and / or a muscle cell specific precursor thereof. Provided is the use of a gene delivery vehicle derived from an adenovirus, having a tropism for said cells, for the preparation of a medicament. In a preferred aspect of the invention, said gene delivery vehicle comprises at least a tropism determining part of an adenoviral fiber protein of subgroup B and / or F. More preferably, said gene delivery vehicle comprises at least part of a fiber protein of an adenovirus of stereotype (11, 16, 35, 40 and / or 51) or a functional part, derivative and / or analogue thereof.

The invention relates to Coxsackievirus B5 CV-B5 CVB5 / JS417 capable of being stably copied and abdicated. The preservation number of the virus is CGMCC (China general microbiological culture collection center) No. 13851. The invention further relates to an application of Coxsackievirus B5 CV-B5 the CVB5 / JS417 in preparing a Coxsackievirus B5 CV-B5 infected mouse. The experimental results show that obvious eosinophilic necrosis and vacuolar degeneration necrosis in spots of the brain, spinal cord, cardiac muscle and skeletal muscle of hind limbs of the Coxsackievirus B5 CV-B5 infected mouse can be seen, and meanwhile, immunohistochemistry shows that positive or strong positive reaction appears in brain and spinal neural cells and cardiac muscle and skeletal muscle cells of the hind limbs, which verifies that the CVB5 / JS417 can cause obvious lesions and necrosis to the brain, spinal nerves, cardiac muscle and skeletal muscle of the hind limbs of the infected mouse.

Methods and kits are provided for separating a mixture of proteins in a biological sample. Methods for detecting and profiling proteins in biological samples by the separation method and kits are also provided. These methods are particularly useful in assessing damage to cells such as cardiac and skeletal muscle cells and in the early clinical diagnosis of myocardial damage by detection of myofilament proteins in serum of a subject.

The invention relates to a probe and method for detecting the glucose transporter protein (GLUT4) membrane, to realize high pass screening. The red fluorescence protein TDimer2 for probe and pH-sensitive fluorescence protein pHluorin mark the insulin-sensitive IRAP protein (TDimer2-IRAP-pHluorin) to establish fat cell system and skeletal muscle cell system for stably expressing the TDimer2-IRAP-pHluorin protein and the effect of the insulin on the target cell can be adjudged by simply measuring the fluorescence ratio. Thus, the high pass screening of the medicine for activating the GLUT4 membrane can be performed by detecting the ratio variance of the pHluorin and TDimer2 fluorescence intensity after medicine activating. The method is simple and easy for high pass screening and industrialization with high sensitivity.